OLMA
Olema Pharmaceuticals, Inc. · Healthcare · Market cap $616.9M
Insiders sold $291K net in the last 90 days ·1 seller, 0 buyers· latest Form 4 filed Jul 27, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$24.7M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Jul 27, 2026
Harmon Cyrus
Olema Pharmaceuticals, Inc. (OLMA) has 15 SEC Form 4 filings (44 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 27, 2026.
Inside the rolling window, 6 insiders at Olema Pharmaceuticals, Inc. reported no open-market purchases and 17 open-market sales totaling $24.7M. The most active filer is Director Harmon Cyrus with 5 filings. Insiders have net sold $1.2M over the trailing 6 months. The most recent open-market filing is a sale of 12,500 shares by Director Harmon Cyrus, dated Jul 23, 2026, worth $145K.
- Industry:Biotechnology
- CEO:Sean Bohen
- Employees:150
- HQ:San Francisco, CA, US
- IPO:2020-11-19
| Source | |||||||
|---|---|---|---|---|---|---|---|
Harmon CyrusFirst in 6 months | Director | Sale | 12,500 | $145K | Jul 27 | -41.3% | SEC ↗ |
Harmon CyrusFirst in 6 months | Director | Sale | 12,500 | $146K | Jul 27 | -41.3% | SEC ↗ |
Mitchell ShawnteFirst filing | CHIEF LEGAL OFFICER | Sale | 15,000 | $345K | Mar 5 | -68.7% | SEC ↗ |
Mitchell ShawnteFirst filing | CHIEF LEGAL OFFICER | Sale | 25,000 | $606K | Mar 5 | -68.7% | SEC ↗ |
| Director | Sale | 10,000 | $269K | Jan 21 | -73.2% | SEC ↗ | |
| Director | Sale | 3,489 | $102K | Jan 16 | -74.0% | SEC ↗ | |
Kovacs Shane William CharlesFirst filing | CH. OPERATING & FINANCIAL OFF. | Sale | 3,822 | $107K | Jan 15 | -75.8% | SEC ↗ |
Kovacs Shane William CharlesFirst filing | CH. OPERATING & FINANCIAL OFF. | Sale | 100,000 | $2.9M | Jan 15 | -75.8% | SEC ↗ |
| CH. DISCOV. & NON-CLIN DEV OFF | Sale | 10,000 | $283K | Jan 14 | -75.5% | SEC ↗ | |
| CH. DISCOV. & NON-CLIN DEV OFF | Sale | 50,000 | $1.4M | Jan 14 | — | SEC ↗ | |
| CH. DISCOV. & NON-CLIN DEV OFF | Sale | 50,000 | $1.4M | Jan 14 | — | SEC ↗ | |
Harmon CyrusFirst filing | Director | Sale | 2,881 | $82K | Dec 29 | — | SEC ↗ |
| Director | Sale | 264,800 | $7.9M | Dec 23 | — | SEC ↗ | |
Zojwalla NaseemFirst filing | Chief Medical Officer | Sale | 70,000 | $2.0M | Dec 23 | — | SEC ↗ |
Zojwalla NaseemFirst filing | Chief Medical Officer | Sale | 100,000 | $2.8M | Dec 23 | — | SEC ↗ |
Zojwalla NaseemFirst filing | Chief Medical Officer | Sale | 99,509 | $2.8M | Dec 23 | — | SEC ↗ |
Myles David C.First filing | CH. DISCOV. & NON-CLIN DEV OFF | Sale | 51,000 | $1.6M | Dec 23 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does OLMA have?
Olema Pharmaceuticals, Inc. (OLMA) has 15 SEC Form 4 filings (44 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Jul 27, 2026.
When was the most recent SEC Form 4 filing for OLMA?
The most recent Form 4 filing for OLMA on Tracefour is dated Jul 27, 2026.
Who is the most active insider at OLMA?
The most active SEC Form 4 filer at OLMA in the rolling window is Director Harmon Cyrus, with 5 filings.
What is the net insider flow at OLMA over the last 6 months?
Over the trailing 180 days, insiders at OLMA have net sold $1.2M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at OLMA in the current window?
Inside the rolling window, insiders at OLMA bought $0 and sold $24.7M based on SEC Form 4 filings.
Can I get alerts for OLMA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Olema Pharmaceuticals, Inc. (OLMA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Olema Pharmaceuticals, Inc. is in the Healthcare sector.